XTL Biopharma Reports Q1 2024 Results, Seeks Strategic Partner

TL;DR

XTLB Q1 results out, exploring partnerships for Lupus/Sjogren's drug.

AI Summary

XTL Biopharmaceuticals Ltd. announced its financial results for the three months ended March 31, 2024. The company, which focuses on treatments for Lupus disease (SLE) and Sjögren’s Syndrome (SS) using its hCDR1 IP portfolio, is exploring strategic partnerships. The filing was made on May 13, 2024.

Why It Matters

This filing provides an update on XTL Biopharma's financial performance and strategic direction, indicating a move towards potential collaborations for its Lupus and Sjögren's Syndrome treatments.

Risk Assessment

Risk Level: medium — The company is clinical-stage and seeking strategic partnerships, indicating ongoing development risks and reliance on external collaborations for future success.

Key Players & Entities

• XTL Biopharmaceuticals Ltd. (company) — Filer and subject of the report
• XTLB (company) — Ticker symbol for XTL Biopharmaceuticals Ltd.
• XTLB.TA (company) — TASE ticker symbol for XTL Biopharmaceuticals Ltd.
• hCDR1 (drug_candidate) — Intellectual property portfolio for treating Lupus and Sjögren's Syndrome
• Lupus disease (SLE) (disease) — Target indication for hCDR1
• Sjögren’s Syndrom (SS) (disease) — Target indication for hCDR1
• May 13, 2024 (date) — Filing date and announcement date
• March 31, 2024 (date) — End of the reporting period for financial results

FAQ

Key Financial Figures

• $430,000 — pital of the Company and the payment of $430,000 to the shareholders of the Social Proxy
• $1,500,000 — itment of an investment of an amount of $1,500,000 through a private placement to be consu
• $1.00 — ts (reflecting a price per each unit of $1.00) consisting of one ADS and one warrant,
• $1.20 — ce into one ADS at an exercise price of $1.20 per warrant. Consummation of the Privat
• $150 thousand — ement, On March 27, 2024, we provided a $150 thousands loan. The loan bears an annual interes
• $1.06 million — h 31, 2024 XTL reported approximately $1.06 million in cash and cash equivalents and approx
• $1.27 million — and cash equivalents and approximately $1.27 million in mainly marketable securities as of M
• $1.40 million — rities as of March 31, 2024 compared to $1.40 million in cash and cash equivalents and approx
• $0.60 million — and cash equivalents and approximately $0.60 million in mainly marketable securities as of D
• $0.34 million — 31, 2023. The decrease of approximately $0.34 million since December 31, 2023, in cash and ca
• $6 thousand — three months ended March 31, 2024 were $6 thousand compared to $13 thousand for the corres
• $13 thousand — h 31, 2024 were $6 thousand compared to $13 thousand for the corresponding period in 2023. T
• $7 thousand — ponding period in 2023. The decrease of $7 thousands in research and development expenses c
• $169 thousand — three months ended March 31, 2024 were $169 thousand compared to $238 thousand for the corre
• $238 thousand — 31, 2024 were $169 thousand compared to $238 thousand for the corresponding period in 2023. T

Filing Documents

• ea0205870-6k_xtlbiophar.htm (6-K) — 58KB
• 0001213900-24-042015.txt ( ) — 59KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: May 13, 2024 XTL BIOPHARMACEUTICALS LTD. By: /s/ Shlomo Shalev Shlomo Shalev Chief Executive Officer 6

View Full Filing

View this 6-K filing on SEC EDGAR